Belluscura Receives Approval in Singapore

Belluscura PLC

12 December 2023

 

Belluscura plc

("Belluscura" or the "Company")

Belluscura Receives Approval to Distribute the X-PLOR Portable Oxygen Concentrator in Singapore 

Distribution of its Portable Oxygen Concentrator to Begin Under InnoMax Licensing Agreement

LONDON, U.K. and PLANO, TX, U.S. (12 December 2023). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received approval from the Singapore Health Sciences Authority to distribute the X-PLOR® portable oxygen concentrator ("POC") in Singapore.

Singapore forms part of the licensed territories covered by the Exclusive License Agreement with InnoMax Medical Device Technologies ("InnoMax") for the manufacture and distribution of Belluscura's portable oxygen concentrators, which was signed in August 2023. InnoMax will pay a minimum royalty and a share of profits on the X-PLOR® device and accessories.

Approximately 5.9% of adults in Singapore above 40 years of age have chronic obstructive pulmonary disease ("COPD"), although this is likely an underestimate as many patients remain undiagnosed*. Singapore is a small country, but it provides a gateway to other ASEAN countries as any medical devices approved in Singapore receive expedited review in, for example, Thailand and in the Philippines.

Regarding the wider region, over 1 million people in Thailand suffer from COPD**.  The medical oxygen systems market in the Philippines is also expected to register a CAGR of 7.10%, reaching USD 86 million on account of increasing prevalence of respiratory diseases resulting from air pollution and smoking, leading to higher demand for oxygen therapy systems amongst patients suffering from COPD***.

Further updates on the Exclusive License Agreement and additional territories covered by the Agreement will be provided by the company as it continues to build out its presence in the region and market its POCs, including the DISCOV-R™.

* Ministry of Health, Singapore - 2018

** https://www.6wresearch.com/industry-report/thailand-oxygen-therapy-equipment-market-outlook

*** https://www.6wresearch.com/industry-report/philippines-medical-oxygen-systems-market-outlook

Bob Rauker, Chief Executive Officer, Belluscura plc, commented:

"We are very excited to receive this approval, enabling us to launch sales in Singapore, as a first market in the ASEAN region. With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing region."

For further information please contact:

Belluscura plc	Tel: [phone]
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Simon Neicheril, Chief Financial Officer
SPARK Advisory Partners Limited Nominated Adviser	Tel: [phone]
Neil Baldwin / Jade Bayat
Dowgate Capital Limited Broker	Tel: [phone]
Russell Cook / Nicholas Chambers
MHP Financial PR & Investor Relations	Tel: [phone] email: [e-mail]
Katie Hunt/Matthew Taylor

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

END